Saranac Partners Ltd Buys 15,629 Shares of Boston Scientific Corporation $BSX

Saranac Partners Ltd raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 25.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 76,646 shares of the medical equipment provider’s stock after purchasing an additional 15,629 shares during the period. Boston Scientific accounts for about 2.9% of Saranac Partners Ltd’s investment portfolio, making the stock its 14th biggest holding. Saranac Partners Ltd’s holdings in Boston Scientific were worth $7,311,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. United Community Bank grew its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Colonial Trust Co SC grew its holdings in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares in the last quarter. Finally, Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported positive pivotal FRACTURE trial results for its investigational SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the device meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The data should help support an FDA filing and strengthens the company’s growth outlook in interventional cardiology. Article Title
• Positive Sentiment: The company also announced a $2 billion accelerated share repurchase program, which signals confidence from management and should help reduce share count, providing a near-term earnings-per-share tailwind. Article Title
• Positive Sentiment: Boston Scientific said it invested $1.5 billion in MiRus for about a 34% stake and obtained an option to buy the startup’s TAVR business, giving BSX a potential path into a large structural heart market and another long-term growth catalyst. Article Title
• Neutral Sentiment: Analyst commentary remained mostly constructive, with several firms reiterating buy/outperform ratings even as some price targets were trimmed, suggesting Wall Street still sees upside despite a lower valuation framework. Article Title
• Neutral Sentiment: Healthcare sector strength also provided a mild tailwind, with the broader group rising late in the session. Article Title
• Negative Sentiment: Offsetting the positives, Robert W. Baird and Bank of America both lowered price targets on BSX, which may temper enthusiasm even though both firms kept constructive ratings. Article Title

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a report on Monday. JPMorgan Chase & Co. cut their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Raymond James Financial reiterated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Wells Fargo & Company dropped their price target on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Stock Up 1.5%

Shares of NYSE:BSX opened at $56.78 on Wednesday. The firm has a market capitalization of $84.39 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.02 and a beta of 0.62. The business has a 50 day simple moving average of $62.77 and a two-hundred day simple moving average of $81.02. Boston Scientific Corporation has a 1 year low of $52.52 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.